COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,100 Articles (22,658 medRxiv, 8,442 bioRxiv)

Most recent first Previous |  Page 76: Articles 751-760  | Next

Demonstration and structural basis of a therapeutic DNA aptamer for SARS-CoV-2 spike protein detection
Liu, Y., Wang, K., Wang, W., Kashyap, S., Jih, J., Imani, A., Hsiai, T., Zhou, Z. H.
10.1101/2025.03.14.643408 — Posted: 2025-03-17
Dissecting the effects of single amino acid substitutions in SARS-CoV2 Mpro
Sreenivasan, S., Fontes, J., Swint-Kruse, L.
10.1101/2025.03.14.643358 — Posted: 2025-03-17
Systemic Multi-Omics Analysis Reveals Interferon Response Heterogeneity and Links Lipid Metabolism to Immune Alterations in Severe COVID-19
Lira-Junior, R., Ambikan, A., Cederholm, A., Rezene, S., Mikaeloff, F., Akusjarvi, S. S., Yalcinkaya, A., Chen, X., Sperk, M., Guillen, M. A., Nordqvist, H., Treutiger, C. J., Landegren, N., Neogi, U., Gupta, S.
10.1101/2025.03.14.643374 — Posted: 2025-03-17
Immune-Coagulation Dynamics in Severe COVID-19: Insights from Autoantibody Profiling and Transcriptomics
Ambikan, A., Cederholm, A., Rezene, S., Guillen, M. A., Nordqvist, H., Treutiger, C. J., Lira-Junior, R., Landegren, N., Gupta, S.
10.1101/2025.03.14.643398 — Posted: 2025-03-17
The impact of the COVID-19 pandemic on secondary prevention of Rheumatic Heart Disease in Western Uganda
Xu, X., Chu, E., Atala, J., Kansiime, R., Nakitto, M., Ndagire, E., Nalubwama, H., Okello, E., Pulle, J., Watkins, D. A., Longenecker, C., Coronado, G., Su, Y.
10.1101/2025.03.14.25323941 — Posted: 2025-03-15
Mental health in the short- and long-term adaptation processes of university students during the COVID-19 pandemic: A systematic review and meta-analysis
Jimenez Villamizar, M. P., Comendador Vazquez, L., Sanabria-Mazo, J. P., Mateo-Canedo, C., Losilla, J.-M., Muro, A., Sanz, A.
10.1101/2025.03.14.25323978 — Posted: 2025-03-15
Cleaved vs. Uncleaved: How Furin Cleavage Reshapes the Conformational Landscape of SARS-CoV-2 Spike
Mani, N., Suresh, R., Chakraborty, S.
10.1101/2025.03.12.642945 — Posted: 2025-03-14
The use of angiotensin-converting enzyme inhibitors but not angiotensin receptor blockers in hospitalized patients with COVID-19 is associated with a lower risk of mortality
Khalangot, M., Gurianov, V., Zakharchenko, T., Kravchenko, V., Kovzun, O., Shupachynskiy, V., Tronko, M.
10.1101/2025.03.12.25323615 — Posted: 2025-03-14
Predictors of first-dose COVID-19 vaccine uptake in Benin: Evidence from a cross-sectional study based on a telephonic survey
AVAHOUNDJE, E. M., BOYI HOUNSOU, C., BELLO, K., VIGAN, A. A., AGOSSOU, M. C., AGBODJAVOU, M. K., GAYE, I., BA, M. F., FAYE, A., RIDDE, V., DOSSOU, J.-P.
10.1101/2025.03.12.25323828 — Posted: 2025-03-14
Strain-specific anti-RBD IgG antibody titers against the WT, XBB.1.5, JN.1, and KP.3 strains consistently correlate with neutralizing activity following SARS-CoV-2 XBB.1.5-adapted mRNA vaccination.
Goto, T., Chong, Y., Sato, T., Tani, N., Saiki, S., Ishida, S., Kawai, N., Bando, T., Ikematsu, H.
10.1101/2025.03.13.25323892 — Posted: 2025-03-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).